Nautilus Biotechnology
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 167
- Market Cap
- $331M
- Introduction
Nautilus Biotechnology, Inc. is a life sciences company, which engages in the development of a proteomics platform for analyzing and quantifying the human proteome. Its products include Proteome Analysis System, Reagent Kits, and Software and Analysis. The company was founded by Sujal Patel and Parag Mallick in 2016 and is headquartered in Seattle, WA.
Clinical Trials
0
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
News
Nautilus Biotechnology Partners with Allen Institute to Advance Alzheimer's Research Through Single-Molecule Proteomics
Nautilus Biotechnology has entered into an agreement with the Allen Institute to investigate the connection between tau protein and Alzheimer's disease using single-molecule proteomics technology.
Amazon Invests $14.7 Million in Proteome Analysis Company Nautilus Biotechnology
Amazon disclosed a $14.7 million investment in Nautilus Biotechnology, a pre-revenue company developing proteome measurement technology for drug discovery and clinical diagnostics.